Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them

A compound of formula (I):

• wherein:
• R1 is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, —C(O)R9, —C(O)Ay, —C(O)Het, —CO2R9, —C(O)NR7R8, —C(O)NR7Ay, —C(S)NR9R11, —C(NH)NR7R8, —C(NH)NR7Ay, —OR7, —OAy, —OHet, —NR7R8, —NR7Ay, —NHHet, —S(O)nR9, —S(O)nAy, —S(O)nHet, —S(O)2NR7R8, —S(O)2NR7Ay, —R10cycloalkyl, —R10Ay, —R10Het, —R10OR9, —R10NR7R8, —R10NR7Ay, —R10NHSO2R9, —R10C(O)R9, —R10C(O)Ay, —R10C(O)Het, —R10CO2R9, —R10OC(O)R9, —R10OC(O)Ay, —R10OC(O)Het, —R10C(O)NR9R11, —R10C(O)NR7Ay, —R10C(O)NHR10Het, —R10C(S)NR9R11, —R10C(NH)NR9R11, —R10SO2R9, —R10SO2NR9R11, —R10SO2NHCOR9, —R10OS(O)nR9, cyano, nitro and azido;
• each R7 and R8 are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, —C(O)R9, —CO2R9, —C(O)NR9R11, —C(S)NR9R11, —C(NH)NR9R11, —SO2R10, —SO2NR9R11, —R10cycloalkyl, —R10Ay, —R10Het, —R10C(O)R9, —R10CO2R9, —R10C(O)NR9R11, —R10C(S)NR9R11, —R10OR9, —R10NR9R11, —R10NHCOR9, —R10NHC(NH)NR9R11, —R10C(NH)NR9R11, —R10NHSO2R9, —R10SO2NR9R11, —R10SO2R10 and —R10SO2NHCOR9;
• each R9 and R11 are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, —R10cycloalkyl, —R10OH, —R10(OR10), where w is 1–10, and —R10NR10R10;
• each R10 is the same or different and is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;
• n is 0, 1 or 2;
• Ay is aryl;
• Het is a 5- or 6-membered heterocyclic or heteroaryl group;
• Y1 is CH;
• p is 0, 1 or 2 when Y1 is CH,
• each R6 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, —C(O)R9, —C(O)Ay, —C(O)Het, —CO2R9, —C(O)NR7R8, —C(O)NR7Ay, —C(S)NR9R11, —C(NH)NR7R8, —C(NH)NR7Ay, —OR7, —OAy, —OHet, —NR7R8, —NR7Ay, —NHHet, —S(O)nR9, —S(O)nAy, —S(O)nHet, —S(O)2NR7R8, —S(O)2NR7Ay, —R10cycloalkyl, —R10Ay, —R10Het, —R10OR9, —R10NR7R8, —R10NR7Ay, —R10NHSO2R9, —R10C(O)R9, —R10C(O)Ay, —R10C(O)Het, —R10CO2R9, —R10OC(O)R9, —R10OC(O)Ay, —R10OC(O)Het, —R10C(O)NR9R11, —R10C(O)NR7Ay, —R10C(O)NHR10Het, —R10C(S)NR9R11, —R10C(NH)NR9R11, —R10SO2R9, —R10SO2NR9R11, —R10SO2NHCOR9, —R10OS(O)nR9, cyano, nitro and azido;
• Y is N or CH;
• R2 is selected from the group consisting of halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, —OR7, —OAy, —OHet —NR7R8, —NR7Ay, —NHHet, —S(O)nR9, —S(O)nAy, —R10NR7R8 and —R10NR7Ay;
• R3 and R4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, —C(O)R7, C(O)Ay, —CO2R7, —CO2Ay, —OR7, —OAy, —NR7R8, —NR7Ay, —NHHet, —SO2NHR9, —R10OR7, —R10cycloalkyl, —R10OAy, —R10NR7R8 and —R10NR7Ay;
• Ring A is selected from the group consisting of aryl, 5–10 membered heterocyclic group and a 5–10 membered heteroaryl group;
• q is 0, 1, 2, 3, 4 or 5;
• and
• each R5 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, —C(O)R9, —C(O)Ay, —C(O)Het, —CO2R9, —C(O)NR7R8, —C(O)NR7Ay, —C(S)NR9R11, —C(NH)NR7R8, —C(NH)NR7Ay, —OR7, —OAy, —OHet, —NR7R8, —NR7Ay, —NHHet, —S(O)nR9, —S(O)2NR7R8, —S(O)2NR7Ay, —R10cycloalkyl, —R10Het, —R10C(O)R9, —R10CO2R9, —R10C(O)NR9R11, —R10C(O)NR7Ay, —R10C(O)NHR10Het, —R10C(S)NR9R11, —R10C(NH)NR9R11, —R10OR9, —R10NR7R8, —R10NR7Ay, —R10SO2R9, —R10SO2NR9R11, —R10SO2NHCOR9, cyano, nitro and azido;
• or
• a pharmaceutically acceptable salt, thereof.